SCHEMBL10243935

SCHEMBL10243935

CCN(CC)Cc1cc(C(C)N(CC)CCNC(=O)OC)ccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
ALOX15 P16050 1/20 0.45
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
APP P05067 3/20 0.41
LMNA P02545 2/20 0.40
ADRA2A P08913 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
DRD2 P14416 1/20 0.40
TSHR P16473 1/20 0.40
DRD3 P35462 1/20 0.40
HTR2B P41595 1/20 0.40
STAT6 P42226 1/20 0.40
KCNH2 Q12809 1/20 0.40
BLM P54132 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HIF1A Q16665 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243744 0.90 POLB (0.41) APPALDH1A1HIF1AACHE
SCHEMBL10282516 0.89 S1PR1 (0.37) PKMALOX15TMEM97SIGMAR1LMNA
SCHEMBL10245320 0.86 S1PR1 (0.36) TMEM97SIGMAR1LMNAADRA2ACYP2D6
SCHEMBL10243957 0.84 L3MBTL1 (0.46) PKMTSHRALDH1A1S1PR1
SCHEMBL10244047 0.83 L3MBTL1 (0.47) PKMTSHRALDH1A1S1PR1
SCHEMBL10243926 0.82 PKM (0.46) PKMALOX15TMEM97SIGMAR1APP
SCHEMBL10243900 0.81 S1PR1 (0.44) LMNACYP2D6CYP2C9ALDH1A1S1PR1
SCHEMBL10244037 0.79 CYP1A2 (0.46) CYP2D6ALDH1A1
SCHEMBL10244482 0.79 POLB (0.45) PKMLMNATSHRALDH1A1
SCHEMBL10244300 0.79 MTNR1A (0.48) PKMAPPALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PKM 4614/4885ALOX15 2677/4885TMEM97 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.